In accordance with the previous study, there was no significant difference in 28-day mortality or rate of adverse events as well as no significant difference in length of stay in hospital or intensive care units (ICU) and sepsis-related organ failure assessment score between the GM-CSF treatment and traditional therapy [30]. Here, CSF2 is linked to Sepsis.